O xidative stress induced by reactive oxygen species (ROS), including superoxide (⅐O 2 Ϫ ), is increased in arterial hypertension, 1 and it has been proposed as a possible mechanism that predisposes to development of atherosclerosis in hypertension. 2 Among other effects, oxidative stress may account for the decrease in the bioavailability of nitric oxide (NO), because it reacts with ⅐O 2 Ϫ . 3 NO has been shown to regulate vascular tone and to inhibit platelet aggregation, thrombus formation, leukocyte adhesion, and vascular proliferation. 4 A plasma membrane-associated NADPH oxidase is present in endothelial cells, vascular smooth muscle cells (VSMCs), and fibroblasts and seems to be the most important source of ⅐O 2 Ϫ in the vessel wall. [5] [6] [7] A major component of NADPH oxidase is the p22 phox protein, a critical subunit that plays an essential role in NADPH oxidase activation in vascular cells. 8 Enhanced vascular NADPH oxidase activity has been shown to be associated with upregulation of p22 phox mRNA in several models of hypertension, including the spontaneously hypertensive rat (SHR). 9 -11 Moreover, increased ROS generation has been found to be associated with augmented vascular NADPH oxidase activity in VSMCs from peripheral arteries in patients with hypertension. 12 The human p22 phox gene has several allelic variants, 13,14 some of which are associated with cardiovascular disease. We recently reported the existence of functional polymorphisms in the p22 phox gene promoter in SHR. 15 In addition, we have described a novel genetic variation in the human p22 phox gene promoter, the Ϫ930 A/G polymorphism, associated with essential hypertension. 16 We have hypothesized that the G allele of the Ϫ930
A/G polymorphism could be associated with higher p22 phox expression and NADPH oxidase activity in patients with essential hypertension. Because NADPH oxidase present in phagocytes, including the p22 phox subunit, is structurally very similar to vascular NADPH oxidase, 1 the studies reported here were performed in these cells. NO metabolites were determined in serum samples of the same subjects to evaluate the potential impact of ⅐O 2 Ϫ production on systemic generation of NO. 17 Furthermore, promoter activity assays were performed in cultured VSMCs obtained from SHR and normotensive Wistar-Kyoto (WKY) rats to address the potential importance of the hypertensive stimulus on the functional activation of this polymorphism.
Methods
An expanded Methods section is available in the online supplement at http://www.hypertensionaha.org.
Subjects
The study was performed in individuals who were referred to our institution for routine medical examination. The hypertensive group comprised 70 subjects with systolic blood pressure Ͼ139 mm Hg, diastolic blood pressure Ͼ89 mm Hg, or both. Half of the patients were receiving antihypertensive treatment when they enrolled in the study. As a control group, 70 normotensive subjects were also studied. Clinical screenings were based on medical history, physical examination, and routine analytical tests. According to institutional guidelines, subjects were aware of the research nature of the study and agreed to participate. The study was carried out in accordance with the Helsinki Declaration, and the Ethical Committee of the University Clinic of Navarra approved the protocol.
Preparation of Phagocytic Cells
Mononuclear phagocytic cells were isolated from blood samples with Lymphoprep.
NADPH Oxidase Activity
Phagocytic cells (400 000 cells) were incubated (37°C for 30 minutes) in basal conditions and with phorbol myristate acetate (PMA; 3.2ϫ10 Ϫ6 mol/L), a protein kinase C (PKC) activator; ⅐O 2 Ϫ production was measured using lucigenin (10 Ϫ5 mol/L). Chemiluminescence was determined every 10 seconds for 5 minutes in a Berthold luminometer. The area under the curve was used to quantify chemiluminescence. Data are expressed as counts per second. In previous experiments, basal and PMA-stimulated ⅐O 2 Ϫ production was completely abolished with apocynin (2.5ϫ10 Ϫ3 mol/L), a specific intracellular inhibitor of NADPH oxidase. Specificity of the lucigenin for ⅐O 2 Ϫ was verified because the addition of the ⅐O 2 Ϫ scavenger superoxide dismutase (SOD; 1000 U/mL) abolished the signal. The lucigenin-based assay was validated against an independent measurement of ⅐O 2 Ϫ production using SOD-inhibitable ferricytochrome C reduction that closely correlated with lucigenin measurements (nϭ5; rϭ0.92, PϽ0.001).
NO Metabolites in Serum
Serum samples were obtained after overnight fasting to measure nitrate and nitrite (NO 2 Ϫ /NO 3 Ϫ , NOx). 18 NOx concentration was evaluated using a colorimetric assay based on Griess reaction. 
Genotyping of the ؊930
A/G Polymorphism of p22 phox Gene
The A-to-G substitution at position Ϫ930 in the p22 phox promoter was typed by restriction fragment length polymorphism as previously described. 16 
Directed Mutagenesis
Transient reporter gene expression assays with chimeric constructs containing A (c1-A) or G (c1-G) allelic p22 phox gene promoter and luciferase gene were performed as previously reported. 15, 16 Transfections were performed on VSMCs from the cell line A7r5 and on VSMCs obtained from SHR and WKY rats. In some experiments, we performed cotransfection of allelic constructs with the CCAAT enhancer-binding protein (C/EBP) ␦ plasmid, generously provided by Professor S.L. McKnight (University of Texas Southwestern Medical Center, Dallas, Tex).
Statistical Analysis
Data are expressed as meanϮSEM. Statistical significance of differences in ⅐O 2 Ϫ generation, p22 phox expression, and NOx levels among groups was assessed by 1-way ANOVA. A Scheffé post hoc test was used to examine differences between groups when significance was achieved. Differences in the luciferase activity between allelic variants were assessed by Student t test.
Results

Clinical Characteristics of the Subjects Studied
The demographic and clinical characteristics of normotensive and hypertensive subjects are shown in Table 1 . Hypertensive subjects exhibited significantly higher values of age, body mass index, and blood pressure than normotensive subjects.
Each subject was genotyped for the Ϫ930 A/G polymorphism. To enhance statistical power, and given the low allelic frequency of the A allele, AA homozygote subjects were added to AG heterozygous subjects. Thus, homogeneous normotensive and hypertensive groups were composed of 35 subjects with GG genotype and 35 subjects with AA/AG genotype (10 individuals AA and 25 individuals AG).
Relation Between the ؊930
A/G Polymorphism and Phagocytic NADPH Oxidase Activity and p22 phox Expression
Although baseline NADPH oxidase activity was similar in hypertensive and normotensive groups (167Ϯ21 counts/s versus 148Ϯ17 counts/s, PϭNS), PMA-stimulated NADPH oxidase activity was higher in hypertensive than in normotensive subjects (1660Ϯ129 counts/s versus 1125Ϯ109 counts/s, PϽ0.01). Whereas baseline NADPH oxidase activity was similar in hypertensive subjects with AA/AG and GG genotype (168Ϯ22 counts/s versus 166Ϯ31 counts/s, PϭNS), PMA-stimulated NADPH oxidase activity was higher in GG than in AA/AG hypertensive subjects (1998Ϯ181 counts/s versus 1322Ϯ112 counts/s, PϽ0.05) (Figure 1 ). No differences in NADPH oxidase activity were observed between AG and AA hypertensive subjects (data not shown). Finally, no differences in PMA-stimulated NADPH oxidase activity were found between AA/AG and GG genotypes in normotensive subjects (1092Ϯ108 counts/s versus 1158Ϯ149 counts/s, PϭNS). p22 phox mRNA levels were higher in GG than in AA/AG hypertensive subjects (1.26Ϯ0.06 AU versus 0.99Ϯ0.03 AU, PϽ0.05) (Figure 2 ). No differences in p22 phox expression were found between AG and AA hypertensive subjects (data not shown). No differences in p22 phox expression were found between AA/AG and GG normotensive subjects (1.00Ϯ0.03 AU versus 1.01Ϯ0.05 AU, PϭNS). These Northern blot data were confirmed by quantitative realtime polymerase chain reaction. In fact, whereas increased p22 phox mRNA levels were observed in GG hypertensive subjects compared with AA/AG hypertensive subjects (1.34Ϯ0.06 AU versus 1.00Ϯ0.04 AU, PϽ0.05), no differences were found between GG and AA/AG normotensive subjects (0.94Ϯ0.03 AU versus 1.00Ϯ0.04 AU, PϭNS).
p22
phox protein abundance was higher in hypertensive than in normotensive subjects (0.46Ϯ0.03 AU versus 0.25Ϯ0.02 AU, PϽ0.01); p22 phox protein expression was higher in GG than in AA/AG hypertensive subjects (0.58Ϯ0.05 AU versus 0.34Ϯ0.04 AU, PϽ0.05) (Figure 2 ). No differences in p22 phox protein expression were found between AA/AG and GG normotensive subjects (0.26Ϯ0.03 AU versus 0.24Ϯ0.04 AU, PϭNS).
The differences in p22 phox expression and NADPH oxidase activity between the 2 hypertensive subgroups were not related to age, gender, body mass index, blood pressure, and metabolic factors because these potentially confounding factors were similar in the 2 subgroups (Table 2 ). In addition, no differences were found in the frequency of antihypertensive drugs and other cardiovascular medication (eg, statins) between the 2 hypertensive subgroups.
Interaction of the ؊930
A/G Polymorphism With Cell Phenotype
To investigate whether the A-to-G substitution may influence gene expression depending on cell phenotype, transfection experiments were carried out on the cell line A7r5 and on VSMCs obtained from WKY and SHR rats, which possess a characteristic normotensive and hypertensive phenotype, respectively. 15 As shown in Figure 3A , the A-to-G substitution increased the reporter gene expression by 30% in hypertensive cells. This allelic change did not modify the reporter gene expression in normotensive cells and in A7r5 cells ( Figure 3B and 3C) .
Because the Ϫ930 polymorphic site lies on a potential binding site for C/EBP transcription factors, additional experiments were carried out on A7r5 cells. Cotransfection of p22 phox allelic constructs with C/EBP␦ increased the p22 phox promoter activity ( Figure 4A ). This effect was significantly 
Figure 1. Effect of the Ϫ930
A/G polymorphism genotype on NADPH oxidase activity. ⅐O 2 Ϫ production was determined by lucigenin chemiluminescence after PMA stimulation in phagocytic cells from 70 normotensive subjects and 70 hypertensive subjects. Bars show meanϩSEM. *PϽ0.05 compared with AA/AG hypertensive subjects and with AA/AG and GG normotensive subjects.
higher on the promoter activity of the G than of the A allelic construct. These results were associated with upregulated C/EBP␦ protein expression, which was nearly absent in C/EBP␦-nontransfected control A7r5 cells ( Figure 4B ).
Association of the ؊930 A/G Polymorphism With NO Production
NOx levels were lower in hypertensive than in normotensive subjects (4.8Ϯ0.2 mol/L versus 6.2Ϯ0.3 mol/L, PϽ0.05). In 
Discussion
The main finding of the present study is that the Ϫ930
A/G polymorphism of the p22 phox gene was associated with p22 phox expression and NADPH oxidase activity in phagocytic cells from patients with essential hypertension. In particular, hypertensive patients carrying the GG genotype exhibited greater p22 phox mRNA and protein levels and NADPH oxidase activity than AA/AG hypertensive patients. These associations were not affected by other confounding variables that are known to influence NADPH oxidase expression and activity (ie, blood pressure, cholesterol, glucose). 19 -21 Therefore, these findings suggest that the Ϫ930 A/G polymorphism is functional in essential hypertension.
Whereas p22 phox mRNA levels were increased in GG hypertensive subjects compared with AA/AG hypertensive subjects, no differences were found in this parameter between the 2 subgroups within the normotensive group. In agreement with this, we found increased luciferase activity driven by the A-to-G substitution in hypertensive but not in normotensive VSMCs. Collectively, these data suggest that the Ϫ930 A/G polymorphism may be functionally relevant in the control of the p22 phox gene expression only under hypertensive conditions. Although the mechanisms that underlie this control remain unclear, one possibility is that the presence of the G allele modulates the transcription of the p22 phox gene. In this regard, an analysis of the promoter sequence shows that the Ϫ930 polymorphic site lies on a potential binding site for C/EBP transcription factors. Furthermore, our results showing a higher effect of C/EBP␦ overexpression in the transcriptional activity of the G rather than of the A allelic p22 phox promoter constructs, enable us to suggest the involvement of C/EBPs in the hypertensive phenotype. Several findings showing a relevant role of C/EBPs in hypertension support this possibility. C/EBP␦ expression is nearly absent in WKY VSMCs, whereas it is abnormally increased in SHR VSMCs. 22 Changes in angiotensinogen mRNA expression associated with the Ϫ217
A/G polymorphism of this gene are regulated by several members of the C/EBP family. 23 Inflammatory cytokines upregulate C/EBP expression, 24 and cytokine levels have been reported to be increased in phagocytic cells in hypertensive patients. 25 Alternatively, the G allele may be in linkage disequilibrium with other genetic variants that influence the transcriptional activity. In this regard, we have identified other polymorphisms in the p22 phox promoter, 26 although their implication in hypertension remains to be established. Recent studies support a role for p22 phox overexpression in hypertension. 27 An increased p22 phox mRNA expression leading to greater NAD(P)H oxidase activity accompanied by diminished NO availability and endothelial dysfunction has been reported in several models of hypertension. 9 -11 Furthermore, angiotensin II-induced generation of ROS by NADPH oxidase is augmented in VSMCs from peripheral arteries of hypertensive patients. 12 Finally, enhanced NADPH oxidasedependent production of ROS in lymphoblasts from subjects with hypertension is associated with a greater p22 phox subunit abundance, but not with changes in the other NADPH oxidase subunits. 28 Therefore, p22 phox overexpression may be a critical determinant of NADPH oxidase overactivity in GG hypertensive subjects. Moreover, the higher ⅐O 2 Ϫ generation observed in GG hypertensive subjects was associated with diminished production of systemic NO. The potential relevance of this finding is further supported by recent research demonstrating that NADPH oxidase is involved in the uncoupling of the endothelial NO synthase, which favors a diminished NO generation in hypertensive animals. 29 Nevertheless, we cannot exclude the existence of oxidative stress in AA/AG hypertensive subjects, which may be mediated by the triggering of other oxidative systems, including uncoupled endothelial NO synthase and xanthine oxidase. 3, 30 In addition, oxidative stress in hypertensive subjects may be also the consequence of a decrease in the activity of antioxidant mechanisms. 31 Preactivated monocytes in hypertensive patients exhibit a higher production of cytokines and a greater adherence to the vascular wall 25, 32 and may play a key role in the oxidative stress-mediated pathogenesis of atherosclerosis. 33 Thus, our data showing increased NADPH oxidase expression and activity in phagocytic mononuclear cells, including monocytes, from GG hypertensive patients suggest this genotype may constitute an important proatherogenic feature in these patients. This possibility is supported by findings demonstrating that the severity of atherosclerosis correlates with p22 phox mRNA overexpression 34 and that p22 phox mutations are able to regulate NADPH oxidase activity in atherosclerosis. 35 Further clinical studies are necessary to ascertain whether the Ϫ930 A/G polymorphism is actually involved in the development of atherosclerosis in hypertensive patients.
Some limitations of the study should be acknowledged. First, the study was performed in a small population, so we are aware that additional studies, including larger numbers of subjects, should be performed to confirm the current results. Second, because PKC activity is upregulated in the vasculature in hypertension, 12, 21 it may be suggested that the NADPH oxidase-activity results in response to PMA, an agonist of PKC, had been provoked by the use of this stimulus. However, the values of NADPH oxidase activity in AA/AG hypertensive subjects were almost identical to those measured in AA/AG normotensive subjects. Thus, we can discard any significant contribution resulting from the stimulus used on the increased NADPH oxidase activity observed in GG hypertensive subjects. Third, although our findings show a greater impact of GG genotype on p22 phox protein abundance than on p22 phox mRNA levels in hypertensive subjects, it may be suggested that genetically determined small changes in p22 phox mRNA levels may play a relevant role in the p22 phox protein expression. In accordance with this, it has been reported that changes in p22 phox phagocytic expression are regulated by posttranscriptional mechanisms. 36 
Perspectives
The findings presented here suggest that the p22 phox gene Ϫ930
A/G polymorphism determines p22 phox expression and NADPH oxidase activity in phagocytic cells from patients with essential hypertension. Increased NADPH oxidase ⅐O 2 Ϫ production might lead to a diminished NO production in GG hypertensive patients. Therefore, the interaction between GG genotype and factors linked to the hypertensive phenotype may be involved in cardiovascular damage mediated by NADPH oxidase-dependent oxidative stress in hypertensive patients.
Figure 5. Association of the Ϫ930
A/G polymorphism with NOx levels. NOx levels were estimated by a colorimetric assay in serum samples from 70 normotensive subjects and 70 hypertensive subjects. Bars show meanϩSEM. *PϽ0.05 compared with AA/AG hypertensive subjects and with AA/AG and GG normotensive subjects.
